Cvrx Inc. is a medical technology company focused on developing and commercializing innovative solutions for the treatment of cardiovascular diseases. The company specializes in advancing minimally invasive therapies that aim to improve heart function and enhance the quality of life for patients suffering from conditions such as heart failure. By leveraging cutting-edge technology and research, Cvrx Inc. is dedicated to addressing the unmet needs in the cardiovascular space and providing healthcare professionals with effective tools to manage patient care. Through its commitment to innovation, the company strives to make a meaningful impact in the field of cardiology and transform patient outcomes. Read More
Curious to know what's happening on the US markets one hour before the close of the markets on Tuesday? Join us as we explore the top gainers and losers in today's session.
Wondering how the US markets performed in the middle of the day on Tuesday? Discover the movers and shakers of today's session in our comprehensive analysis.
The US market is yet to commence its session on Tuesday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.
New real-world evidence presented at THT 2025 and published simultaneously in the Journal of Cardiac Failure (JCF) demonstrates large and statistically significant reductions in hospital visits and length of stay in patients with heart failure and reduced ejection fraction
MINNEAPOLIS, Feb. 04, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced its financial and operating results for the fourth quarter and full year of 2024.
